BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

23andMe, Inc. and MediGuard.org Conducting Rheumatoid Arthritis Study Sponsored by Janssen Healthcare Innovation, a Unit of Janssen Research & Development, LLC


7/18/2012 9:04:34 AM

July 18, 2012 -- Janssen Healthcare Innovation, a unit of Janssen Research & Development, LLC, is sponsoring a study in rheumatoid arthritis patients that will be conducted by MediGuard.org (a subsidiary of Quintiles) and 23andMe.

The study, called TogetherRA, will enroll approximately 1,000 patients who are currently receiving or have previously received anti-TNF-alpha therapeutics for their rheumatoid arthritis. MediGuard.org will recruit patients directly out of its 2.7 million member patient community and, with patients’ consent, will gather information related to patients’ diagnosis and response to treatment from medical records.

23andMe will be responsible for genotyping patients, collecting patient-reported outcomes data, integrating medical record data, as well as conducting a genome-wide analysis that will explore genetics and patients’ response to anti-TNF-alpha therapeutics. Notably, all participants in this study will receive access to their own genetic data. 23andMe is excited to conduct this important research in rheumatoid arthritis.

Janssen Healthcare Innovation is sponsoring this study as part of its initiative to explore a direct-to-patient research model and utilize novel ways to conduct research and support an empowered patient experience.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->